Clinical Scorecard: FDA Reshapes Drug Testing Approach

At a Glance

Key Highlights

• FDA met initial 1-year milestones in its April 2025 roadmap to reduce animal testing in preclinical safety studies.
• New approach methodologies include in vitro systems, computational toxicology, human-derived platforms, and AI-based tools.
• Draft guidances issued to reduce nonhuman primate testing and transition from horseshoe crab–derived endotoxin testing.

Guideline-Based Recommendations

Diagnosis

• Recognize limitations of animal models due to poor predictive value for human safety and efficacy.

Management

• Implement alternative testing methods when they demonstrate equivalent or improved predictive performance compared to animal models.
• Apply weight-of-evidence approaches integrating nonanimal data sources across multiple safety endpoints.

Monitoring & Follow-up

• Use FDA’s searchable database to identify where alternative methods are acceptable in regulatory submissions.
• Collaborate with international regulators and NIH to evaluate emerging drug development tools.

Risks

• Potential safety or efficacy concerns may not be detected if relying solely on animal models due to their limited predictive value.

Patient & Prescribing Data

Not applicable (focus on preclinical drug development)

Reduction in animal testing may lower drug development costs and accelerate availability of safer drugs for patients.

Clinical Best Practices

• Adopt alternative testing methodologies validated for predictive accuracy to reduce reliance on animal models.
• Incorporate computational and laboratory-based assays in safety evaluations.
• Stay informed on FDA guidances and utilize available resources such as AI tools and regulatory databases.

Related Resources & Content

• FDA Press Release on Drug Testing Roadmap